ABSTRACT
The discovery of 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid 13n (ceralifimod, ONO-4641), a sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5, is described. While it has been revealed that the modulation of the S1P1 receptor is an effective way to treat autoimmune diseases such as relapsing-remitting multiple sclerosis (RRMS), it was also reported that activation of the S1P3 receptor is implicated in some undesirable effects. We carried out a structure-activity relationship (SAR) study of hit compound 6 with an amino acid moiety in the hydrophilic head region. Following identification of a lead compound with a dihydronaphthalene central core by inducing conformational constraint, optimization of the lipophilic tail region led to the discovery of 13n as a clinical candidate that exhibited >30â¯000-fold selectivity for S1P1 over S1P3 and was potent in a peripheral lymphocyte lowering (PLL) test in mice (ED50 = 0.029 mg/kg, 24 h after oral dosing).
Subject(s)
Azetidines/pharmacology , Lymphocytes/drug effects , Naphthalenes/pharmacology , Receptors, Lysosphingolipid/agonists , Administration, Oral , Animals , Autoimmune Diseases/drug therapy , Azetidines/administration & dosage , Azetidines/chemistry , Azetidines/pharmacokinetics , CHO Cells , Cricetulus , Female , Humans , Macaca fascicularis , Male , Mice , Mice, Inbred BALB C , Naphthalenes/administration & dosage , Naphthalenes/chemistry , Naphthalenes/pharmacokinetics , Rats, Inbred Lew , Rats, Sprague-DawleyABSTRACT
We recently reported that 4-epi-jaspine B exhibits potent inhibitory activity towards sphingosine kinases (SphKs). In this study, we investigated the effects of modifying the 2-alkyl group, as well as the functional groups on the THF ring of 4-epi-jaspine B using a diversity-oriented synthesis approach based on a late-stage cross metathesis reaction. The introduction of a p-phenylene tether to the alkyl group was favored in most cases, whereas the replacement of a carbon atom with an oxygen atom led to a decrease in the inhibitory activity. Furthermore, the introduction of a bulky alkyl group at the terminus led to a slight increase in the inhibitory activity of this series towards SphKs compared with 4-epi-jaspine B (the Q values of compound 13 for SphK1 and SphK2 were 0.2 and 0.4, respectively). Based on this study, we identified two isoform selective inhibitors, including the m-phenylene derivative 4 [IC50 (SphK1) ≥30µM; IC50 (SphK2)=2.2µM] and the methyl ether derivative 22 [IC50 (SphK1)=4.0µM; IC50 (SphK2) ≥30µM].
Subject(s)
Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Sphingosine/analogs & derivatives , Humans , Molecular Docking Simulation , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Sphingosine/chemistry , Sphingosine/pharmacology , Structure-Activity RelationshipABSTRACT
The structure of the S1P2 antagonist 1 has been modified with the aim of improving its oral bioavailability. The chemical modification of the alkyl chain and carboxylic acid moieties of 1 led to significant improvements in the oral exposure of compounds belonging to this series. The optimization of the ring size of the urea portion of these molecules also led to remarkable improvements in the oral exposure. Based on these changes, the pyrrolidine derivative 16 was identified as a suitable candidate compound and showed excellent pharmacokinetic profiles in rat and dog, while maintaining high levels of potency and selective antagonistic activity toward S1P2.
Subject(s)
Benzene Derivatives/chemistry , Receptors, Lysosphingolipid/antagonists & inhibitors , Administration, Oral , Animals , Benzene Derivatives/chemical synthesis , Benzene Derivatives/pharmacokinetics , Biological Availability , Dogs , Drug Evaluation, Preclinical , Half-Life , Haplorhini , Pyrrolidines/chemical synthesis , Pyrrolidines/chemistry , Pyrrolidines/pharmacokinetics , Rats , Receptors, Lysosphingolipid/metabolism , Sphingosine-1-Phosphate Receptors , Structure-Activity RelationshipABSTRACT
Our initial lead compound 2 was modified to improve its metabolic stability. The resulting compound 5 showed excellent metabolic stability in rat and human liver microsomes. We subsequently designed and synthesized a hybrid compound of 5 and the 1,3-bis(aryloxy) benzene derivative 1, which was previously reported by our group to be an S1P2 antagonist. This hybridization reaction gave compound 9, which showed improved S1P2 antagonist activity and good metabolic stability. The subsequent introduction of a carboxylic acid moiety into 9 resulted in 14, which showed potent antagonist activity towards S1P2 with a much smaller species difference between human S1P2 and rat S1P2. Compound 14 also showed good metabolic stability and an improved safety profile compared with compound 9.
Subject(s)
Benzene Derivatives/pharmacology , Drug Discovery , Receptors, Lysosphingolipid/antagonists & inhibitors , Animals , Benzene Derivatives/chemistry , Benzene Derivatives/metabolism , Dose-Response Relationship, Drug , Humans , Molecular Structure , Rats , Receptors, Lysosphingolipid/metabolism , Sphingosine-1-Phosphate Receptors , Structure-Activity RelationshipABSTRACT
The structure-activity relationships of a novel series of sphingosine-1-phosphate receptor antagonists have been examined in detail. The initial hit compound 1 was modified through synthesis to improve its S1P2 activity. The synthesis of a series of analogs revealed that 1,3-bis(aryloxy)benzene derivatives, as represented by 22, are potent and selective S1P2 antagonists.
Subject(s)
Benzene Derivatives/pharmacology , Drug Discovery , Receptors, Lysosphingolipid/antagonists & inhibitors , Benzene Derivatives/chemical synthesis , Benzene Derivatives/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Sphingosine-1-Phosphate Receptors , Structure-Activity RelationshipABSTRACT
Structure-activity relationship (SAR) of sphingosine-1-phosphate receptor agonists with a dihydronaphthalene scaffold was investigated. Compound 1 was modified to improve S1P(1) agonistic activity and in vivo peripheral lymphocyte lowering (PLL) activity without impairing selectivity over S1P(3) agonistic activity. A detailed SAR study of the terminal lipophilic part revealed that the introduction of substituents on the propylene linker and the terminal benzene ring influences in vitro and PLL activities. Compound 6n bearing a (S)-methyl group at the 2-position on the propylene linker and chlorine at the para-position on the terminal benzene ring showed potent hS1P(1) agonistic activity with excellent selectivity over hS1P(3) and in vivo PLL activity in mice.
Subject(s)
Chemistry, Pharmaceutical/methods , Lysophospholipids/antagonists & inhibitors , Naphthalenes/chemistry , Receptors, Lysosphingolipid/antagonists & inhibitors , Sphingosine/analogs & derivatives , Administration, Oral , Animals , Benzene/chemistry , Chlorine/chemistry , Drug Design , Humans , Ligands , Mice , Models, Chemical , Rats , Sphingosine/antagonists & inhibitors , Structure-Activity RelationshipABSTRACT
Structure-activity relationship of sphingosine-1-phosphate receptor agonists was examined. Cinnamyl derivative 1 was modified to improve S1P(1) agonistic activity as well as selectivity over S1P(3) agonistic activity. Dihydronaphthalene derivative 10d was identified as a potent S1P(1) receptor agonist with high selectivity against S1P(3) and enhanced efficacy in lowering peripheral lymphocyte counts in mice.
Subject(s)
Naphthalenes/chemical synthesis , Propanols/chemistry , Receptors, Lysosphingolipid/agonists , Administration, Oral , Animals , CHO Cells , Cricetinae , Cricetulus , Fingolimod Hydrochloride , Humans , Lymphocytes/drug effects , Mice , Molecular Structure , Naphthalenes/administration & dosage , Naphthalenes/pharmacology , Propanols/administration & dosage , Propanols/pharmacology , Propylene Glycols , Sphingosine/analogs & derivatives , Structure-Activity RelationshipABSTRACT
Structure-activity relationship of sphingosine-1-phosphate receptor agonist was examined. In terms of reducing the flexibility of molecule, hit compound 1 was modified to improve S1P(1) agonistic activity as well as selectivity over S1P(3) agonistic activity. Novel S1P agonists with cinnamyl scaffold or 1,2,5,6-tetrahydropyridine scaffold were identified.
